0001123292-24-000200.txt : 20240724
0001123292-24-000200.hdr.sgml : 20240724
20240723174355
ACCESSION NUMBER: 0001123292-24-000200
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20240724
DATE AS OF CHANGE: 20240723
EFFECTIVENESS DATE: 20240724
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Phio Pharmaceuticals Corp.
CENTRAL INDEX KEY: 0001533040
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-519563
FILM NUMBER: 241135646
BUSINESS ADDRESS:
STREET 1: 11 APEX DRIVE, SUITE 300A
STREET 2: PMB 2006
CITY: MARLBOROUGH
STATE: MA
ZIP: 01752
BUSINESS PHONE: (508) 767-3861
MAIL ADDRESS:
STREET 1: 11 APEX DRIVE, SUITE 300A
STREET 2: PMB 2006
CITY: MARLBOROUGH
STATE: MA
ZIP: 01752
FORMER COMPANY:
FORMER CONFORMED NAME: RXi Pharmaceuticals Corp
DATE OF NAME CHANGE: 20111019
D
1
primary_doc.xml
X0708
D
LIVE
0001533040
Phio Pharmaceuticals Corp.
11 Apex Drive
Suite 300A, PMB 2006
Marlborough
MA
MASSACHUSETTS
01752
508-767-3861
DELAWARE
RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corp
Corporation
true
Robert
J.
Bitterman
11 Apex Drive
Suite 300A, PMB 2006
Marlborough
MA
MASSACHUSETTS
01752
Director
Executive Officer
Patricia
A.
Bradford
11 Apex Drive
Suite 300A, PMB 2006
Marlborough
MA
MASSACHUSETTS
01752
Director
Robert
L.
Ferrara
11 Apex Drive
Suite 300A, PMB 2006
Marlborough
MA
MASSACHUSETTS
01752
Director
Jonathan
E.
Freeman
11 Apex Drive
Suite 300A, PMB 2006
Marlborough
MA
MASSACHUSETTS
01752
Director
Curtis
A.
Lockshin, Ph.D.
11 Apex Drive
Suite 300A, PMB 2006
Marlborough
MA
MASSACHUSETTS
01752
Director
Biotechnology
Decline to Disclose
- 06b
false
2024-07-11
false
true
true
false
0
H.C. Wainwright & Co., LLC
375
None
None
430 Park Avenue
3rd Floor
New York
NY
NEW YORK
10022
IL
ILLINOIS
NY
NEW YORK
TX
TEXAS
6358543
136322
6222221
The offering amount reflects the aggregate purchase price received and exercise price due to the Company assuming cash exercise of all warrants issued to the accredited investors and placement agent in the private placement under Rule 506(b).
false
8
349191
0
In connection with the offering, the placement agent received $379,191 and warrants to purchase up to 40,896 shares of common stock exercisable at $6.8125 per share.
0
Phio Pharmaceuticals Corp.
/s/ Robert J. Bitterman
Robert J. Bitterman
President and Chief Executive Officer
2024-07-23